Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients
Table 1
Demographic and clinical features.
Characteristics
Number
%
Characteristics
Number
%
Age, years (median, IQR)
60 (18–93)
ASA class
Sex
1-2
1020
95.4
Male
795
74.4
≥3
49
4.6
Female
274
25.6
Type of surgery
CEA level
Total gastrectomy
284
26.6
Normal
871
81.5
Subtotal gastrectomy
785
73.4
Above normal
116
10.9
Type of LN dissection
Unknown
82
7.7
D1
11
1.0
CA 19–9 level
D1+
549
51.3
Normal
826
77.3
D2
509
47.7
Above normal
152
14.2
Lymphovascular invasion
Unknown
91
8.5
No
945
88.4
Differentiation
Yes
93
8.6
Well or moderate
603
56.4
Unknown
31
2.9
Poor
466
43.6
T stage
Tumor size, cm
T1
821
76.8
<3
590
55.2
T2
248
23.3
≥3
479
44.8
N stage
Tumor location
N0
895
83.7
Lower
595
55.7
N1
174
16.3
Middle
138
12.9
TNM stage
Upper
207
19.4
IA
635
59.4
Multiple
129
12.0
IB
434
40.6
Haemoglobin, g/l (median, IQR)
135 (53–174)
AC
Albumin, g/l (median, IQR)
40 (20–52)
No (surgery alone)
925
86.5
WBC, 109/l (median, IQR)
6.0 (2.7–16.6)
Yes (surgery + AC)
144
13.5
Neutrophils, 109/l (median, IQR)
3.5 (0.7–14.6)
Pretreatment hypoalbuminemia
Platelets, 109/l (median, IQR)
217 (80–523)
No
895
83.7
dNLR
Yes
174
16.3
<2
797
74.6
≥2
272
25.4
IQR = interquartile range; AC = adjuvant chemotherapy; dNLR = neutrophil count to (white cell count minus neutrophil count); ASA = American Society of Anesthesiologists. Pretreatment hypoalbuminemia: pretreatment serum albumin < 35 g/l.
